Feature | March 06, 2013| Dave Fornell

The Radial Access Adoption Report Card

Over the past decade in the United States, there has been growing interest in transradial artery percutaneous access as a way to significantly reduce bleeding rates and access site complications. However, adoption in the United States has been slow compared to other parts of the world, partly due to lack of training in interventional programs until recently. In articles and sessions at various cardiology conferences, I have heard varying U.S. adoption rate percentages.  

One of the biggest advocates for expanding radial access is Sunil V. Rao, M.D., FACC, assistant professor of medicine at Duke University Medical Center and director of the cardiac cath lab at the Durham VA Medical Center, Durham, N.C. He asked the same question about U.S. radial access usage and found it accounted for 3 percent of cath lab access in his 2008 study[1] of the American College of Cardiology’s CathPCI Registry of the National Cardiovascular Data Registry (NCDR). The CathPCI Registry collects data from about 85 percent of the cardiac cath labs in the United States.

Since 2008, there has been a big push from radial evangelists such as Rao and others to spread the word about the benefits of radial access.  That message has been amplified in recent years in an era of reduced reimbursements and healthcare reform forcing hospitals to look for new ways to reduce costs, including reducing hospital length of stay and complications.

An updated NCDR snapshot of radial access between January 2010 and June 2011 was published in December 2012.  The study showed radial access usage rose to 8.3 percent[2], based on a review of 1.1 million patients undergoing diagnostic cardiac catheterization and 941,248 undergoing percutaneous coronary intervention (PCI). 

This growth rate combined with the introduction of radial training programs in recent years has some experts now predicting a 15 percent radial access usage rate by 2014. 

I wrote a column three years ago that asked why radial access is not more widely used if study after study shows it can slash complication rates, increase patient safety and reduce length of stay and nursing time?  The question I posed then still stands. Out of all the columns and articles ever written in DAIC, that column generated, by far, the most reader comments we ever received. DAIC’s most read website content also includes several transradial access stories in the top 20 articles for 2012. 

One major change that could spur radial’s increased usage would be recognition of its benefits by the Centers for Medicare and Medicaid Services (CMS) by offering higher reimbursements for radial over femoral access. From the level of evidence seen in studies, this increased cost would be offset downstream by greatly lowering the costs to treat complications. 

 

References: 

 

1. Sunil V. Rao, Fang-Shu Ou, Tracy Y. Wang, et al. “Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention.” J Am Coll Cardiol Intv. 2008;1(4):379-386. doi:10.1016/j.jcin.2008.05.007.

2. Gregory J. Dehmer, Douglas Weaver, Matthew T. Roe, et al. “A Contemporary View of Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention in the United States A Report From the CathPCI Registry of the National Cardiovascular Data Registry, 2010 Through June 2011.” J Am Coll Cardiol. 2012;60(20):2017-2031. doi:10.1016/j.jacc.2012.08.966

 

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Overlay Init